Buy or sell Adimab stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Adimab Stock
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
About Adimab Stock
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Funding History
July 2007 | $6.2M |
---|---|
July 2007 | $2K |
September 2007 | $5.9M |
March 2008 | $3.2M |
November 2008 | $4.0M |
January 2010 | $8.2M |
December 2010 | $4.0M |
April 2012 | $14.0M |
Management
General Counsel
Philip Chase
Advisor
Colin Greenspon
VP, Head, Business Development
Guy Van Meter
Co-founder, Chair of the SAB
K. Dane Wittrup
Board Member
Tillman Gerngross
Founder, CEO
Tillman Gerngross
Board of Directors
Carl L. Gordon
Member of the Board of Directors
Bill Maris
VP Computational Biology
Max Vasquez
Chief Scientific Officer
Eric Krauland
Director, Open Innovation
Piotr Bobrowicz
Co-Founder
Errik Anderson
Member of the Board of Directors
Terrance McGuire
Press
MIT Scientist’s Biotech Research Is Called Into Question
Wall Streets Journal - May, 26 2019
Mithril Capital Management, cofounded by Ajay Royan and Peter Thiel, is leaving the Bay Area
TechCrunch - Sep, 21 2018
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase